EHA 2024 | Results from Five Studies of Ascentage Pharma’s Key Drug Candidates Selected for Presentations at 2024 European Hematology Association Hybrid Congress

May 16, 2024 | blog

SUZHOU, China and ROCKVILLE, Md., May 15, 2024 /PRNewswire/ — Ascentage Pharma (6855.HK), a world biopharmaceutical firm engaged in growing novel therapies for most cancers, power hepatitis B (CHB), and age-related illnesses, introduced as we speak that the most recent outcomes from 5 research have been chosen for Poster Presentations on the 2024 European Hematology Association Hybrid Congress (EHA 2024). These posters will characteristic olverembatinib (HQP1351), the primary and solely China-approved third-generation BCL-ABL1 inhibitor; investigational lisaftoclax (APG-2575), a Bcl-2 selective inhibitor; and investigational APG-5918, an EED selective inhibitor.

The European Hematology Association (EHA) Hybrid Congress is the most important gathering of the hematology area in Europe. It showcases essentially the most cutting-edge analysis and state-of-the-art revolutionary therapies, attracting over 10,000 medical specialists and researchers from greater than 100 nations yearly. This yr, the EHA Hybrid Congress will happen on June 13 – 16, 2024, in Madrid, Spain.

“I am delighted to showcase the strength and progress of Ascentage Pharma in hematology at this year’s congress, especially the therapeutic potential and clinical value  of its drug candidates in chronic myeloid leukemia (CML), Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), multiple myeloma (MM), immunoglobulin light-chain (AL) amyloidosis, and anemia diseases,” stated Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma. “We look forward to sharing the detailed results at the congress. In the future, we will continue to advance those development programs in efforts to bring more treatment options to patients around the world.”

The 5 research to be offered at EHA 2024 are as follows:

  • Olverembatinib

Olverembatinib Overcomes Ponatinib and Asciminib Resistance in Patients (Pts) with Heavily Pretreated Chronic Myeloid Leukemia (CML) and Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph º  ALL)

¢     Abstract#: P722
¢     Presentation Type: Poster presentation
¢     Topic: Chronic myeloid leukemia “ Clinical
¢     Date & Time: Friday June 14, 2024, 18:00 – 19:00 CEST
¢     Presenting Author: Dr. Elias  Jabbour, The University of Texas MD Anderson Cancer Center

Combination  of Third Generation  TKI Olverembatinib and Chemotherapy or Blinatumomab for New Diagnosed Adult Ph+  ALL Patients

¢     Abstract#: P427
¢     Presentation Type: Poster presentation
¢     Topic: Acute  lymphoblastic leukemia “ Clinical
¢     Date & Time: Friday June 14, 2024, 18:00 – 19:00  CEST
¢     Presenting Author:  Junjie Chen, Nanfang Hospital, Southern Medical University

Patient Reported Outcomes in Adults with TKI-Resistant Chronic Myeloid Leukemia Receiving Olverembatinib-Therapy

¢     Abstract#: P1862
¢     Presentation Type:  e-Poster presentation
¢     Topic: Chronic myeloid leukemia “ Clinical
¢     Date & Time: Friday June 14, 2024, 18:00 – 19:00 CEST
¢     Presenting Author:  Lu Yu, Peking University People’s Hospital

  • Lisaftoclax

Lisaftoclax (APG-2575) Combined with Novel Therapeutic Regimens in Patients (Pts) with Relapsed or Refractory (R/R) Multiple Myeloma (MM) or Immunoglobulin Light-Chain (AL) Amyloidosis

¢     Abstract#: P917
¢     Presentation Type: Poster presentation
¢     Topic: Myeloma and different monoclonal gammopathies “ Clinical
¢     Date & Time: Friday June 14, 2024, 18:00 – 19:00 CEST
¢     Presenting Author: Dr.  Sikander Ailawadhi, Mayo Clinic Florida

Embryonic Ectoderm Development (EED) Inhibitor APG-5918 Improves Chronic Kidney Disease- (CKD)-Induced Hemoglobin (HB) Insufficiency in Preclinical Models of Anemia

¢     Abstract#: P1550
¢     Presentation Type: Poster presentation
¢     Topic:  Enzymopathies, membranopathies and different anemias
¢     Date & Time: Friday June 14, 2024, 18:00 – 19:00 CEST
¢     Presenting Author: Dr. Eric  Liang, Ascentage Pharma Group Inc.

About Ascentage Pharma

Ascentage Pharma (6855.HK) is a globally centered biopharmaceutical firm engaged in growing novel therapies for cancers, power hepatitis B, and age-related illnesses. On October 28, 2019, Ascentage Pharma was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the inventory code 6855.HK.

Ascentage Pharma focuses on growing therapeutics that inhibit protein-protein interactions to revive apoptosis, or programmed cell dying. The firm has constructed a pipeline of 9 medical drug candidates, together with novel, extremely potent Bcl-2, and twin Bcl-2/Bcl-xL inhibitors, in addition to candidates aimed toward IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors (TKIs). Ascentage Pharma can also be the one firm on this planet with energetic medical packages focusing on all three identified lessons of key apoptosis regulators. The firm is conducting greater than 40 Phase I/II medical trials, together with 5 international registrational section III research, within the US, Australia, Europe, and China. Ascentage Pharma has been designated for a number of Major National R&D Projects, together with 5 Major New Drug Projects, one New Drug Incubator standing, 4 Innovative Drug Programs, and one Major Project for the Prevention and Treatment of Infectious Diseases.

Olverembatinib, the corporate’s core drug candidate developed for the therapy of drug-resistant power myeloid leukemia (CML) and the corporate’s first accredited product, has been granted Priority Review Designations and Breakthrough Therapy Designations by the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA). To date, the drug had been included into the China 2022 National Reimbursement Drug List (NRDL). Furthermore, olverembatinib has been granted an Orphan Drug Designation (ODD) and a Fast Track Designation (FTD) by the US FDA, and an Orphan Designation by the EMA of the EU. To date, Ascentage Pharma has obtained a complete of 16 ODDs from the US FDA and 1 Orphan Designation from the EMA of the EU for 4 of the corporate’s investigational drug candidates.

Leveraging its strong R&D capabilities, Ascentage Pharma has constructed a portfolio of world mental property rights and entered into international partnerships with quite a few famend biotechnology and pharmaceutical corporations and analysis institutes equivalent to UNITY Biotechnology, MD Anderson Cancer Center, Mayo Clinic, Dana-Farber Cancer Institute, MSD, and AstraZeneca (NASDAQ:). The firm has constructed a proficient workforce with international expertise within the discovery and improvement of revolutionary medication and is establishing its world-class business manufacturing and Sales & Marketing groups. One pivotal goal of Ascentage Pharma is to repeatedly strengthen its R&D capabilities and speed up its medical improvement packages, with a purpose to fulfil its mission of addressing unmet medical wants in China and all over the world for the good thing about extra sufferers.

Forward-Looking Statements

The forward-looking statements made on this article relate solely to the occasions or info as of the date on which the statements are made on this article. Except as required by legislation, Ascentage Pharma undertakes no obligation to replace or revise publicly any forward-looking statements, whether or not because of new info, future occasions, or in any other case, after the date on which the statements are made or to replicate the incidence of unanticipated occasions. You ought to learn this text fully and with the understanding that our precise future outcomes or efficiency could also be materially completely different from what we count on. In this text, statements of, or references to, our intentions or these of any of our Directors or our Company are made as of the date of this text. Any of those intentions might alter in gentle of future improvement.

MoneyMaker FX EA Trading Robot

powered by